Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Trial Profile

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs CAEL 101 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Dec 2018 Results of phase 1b evaluating the effects of CAEL-101 in patients with cardiac amyloidosis presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 According to a Caelum Biosciences media release, results from this trial were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
    • 04 Dec 2018 Results presented in the Caelum Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top